局限性前列腺癌放疗后患者自报性辅助器具使用与疗效
该研究纳入2008至2013年接受超低分次放疗的471例局限性前列腺癌患者,中位随访60个月,24个月和60个月勃起功能保留率分别为53%和41%,基线37%使用性辅助器具,至60个月70%尝试过,自报疗效高且持续,但部分认为器具有效者未持续使用。
要点
- 基线37%使用性辅助器具,至60个月70%尝试过。
- 24和60个月勃起功能保留率分别为53%和41%。
- 器具自报疗效高且持续,但部分有效者未持续使用。
核心结论
- 约三分之一患者在基线使用性辅助器具,放疗后5年翻倍至70%。
- 自报器具疗效高且持续,但勃起功能显著下降。
- 部分认为器具有效者未持续使用,需未来研究了解使用驱动因素。
研究设计与样本
- 2008至2013年连续471例局限性前列腺癌患者接受超低分次放疗,来自2项机构方案或前瞻性注册研究。
- 勃起功能定义依据EPIC-26为「足够坚硬以进行性交」,无论是否使用辅助器具,基线分析队列n=222。
主要发现
- 中位随访60个月,中位年龄67岁,70%为中危或高危疾病。
- 24和60个月问卷应答率分别为86%和67%,勃起功能保留率分别为53%和41%。
- 基线37%(n=82)使用性辅助器具,多因素分析中与24个月勃起功能保留较低相关(调整OR 0.49,95%CI 0.26-0.92)。
- 至60个月70%男性尝试过辅助器具;基线认为器具有效者中84%至89%在24至60个月报告持续获益。
关键数值与推荐
- 勃起功能保留定义为EPIC-26「足够坚硬以进行性交」,无论是否使用辅助器具。
- 性辅助器具使用和疗效为患者自报。
临床怎么用
- 放疗后应主动评估性辅助器具使用情况,鼓励有效者持续使用以优化性功能。
局限性
- 基线勃起功能分析仅限n=222患者,结果适用于该队列。
- 问卷应答率在60个月降至67%,可能存在应答偏倚。
- 性辅助器具使用和疗效均为患者自报。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report sexual health-related quality of life outcomes and utilization and efficacy of sexual aids in a contemporary cohort of patients treated for localized prostate cancer. PATIENTS AND METHODS: Between 2008 and 2013, 471 consecutive men with localized prostate cancer were treated on 2 institutional protocols (NCT01766492, NCT01618851) or on a prospective institutional registry with patient-reported health-related quality of life. All patients were treated with ultra-hypofractionated radiation therapy. Erectile function (EF) was defined as "firm enough for intercourse" with or without aids per Expanded Prostate Cancer Index Composite-26 (n = 222 at baseline); results apply to this cohort unless specifically noted. Sexual aid utilization and efficacy were patient reported. Multivariable analysis of EF was performed. RESULTS: Median follow-up was 60 months, median age was 67 years, and 70% had intermediate- or high-risk disease per National Comprehensive Cancer Network guidelines. At 24 and 60 months, questionnaire response rates were 86% and 67%, and EF was retained in 53% and 41%, respectively. Baseline sexual aid utilization was 37% (n = 82) and was associated with lower 24-month EF preservation on multivariable analysis (adjusted odds ratio 0.49, 95% confidence interval 0.26-0.92). By 60 months, 70% of men had tried aids. Of those who found aids helpful at baseline, 84% to 89% reported continued benefit at 24 to 60 months. Among aid-naïve patients, efficacy was 80% with first-time use within 12 months and 70% more than 12 months after radiation therapy (P = .02). Among men who developed erectile dysfunction but found sexual aids helpful, 25% were not current users at 60 months. CONCLUSIONS: One-third of men used sexual aids at baseline, which doubled by 5 years after radiation therapy. Self-reported efficacy was high and sustained. Despite significant declines in EF, a number of men reported helpfulness of aids but were not active users. Future study is required to understand drivers of aid utilization to optimize posttreatment sexual function.
引用
- Dess RT, Devasia TP, Aghdam N, et al. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29487023. doi:10.1016/j.ijrobp.2018.01.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。